In COVID-19, tocilizumab reduces all-cause mortality at 28 d.

Shannon M Fernando; Bram Rochwerg

首页> 外文期刊>Annals of Internal Medicine >In COVID-19, tocilizumab reduces all-cause mortality at 28 d.

【24h】

In COVID-19, tocilizumab reduces all-cause mortality at 28 d.

机译：在Covid-19中，Tocilizumab在28天降低全导致死亡率。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;3:CD013881. 33734435.

机译：None

著录项

来源
《Annals of Internal Medicine》 |2021年第6期|共1页
作者
Shannon M Fernando; Bram Rochwerg;
展开▼
作者单位

University of Ottawa;

McMaster University;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学;
关键词

相似文献

外文文献
专利

1. Association Analysis of Hyperlipidemia with the 28-Day All-Cause Mortality of COVID-19 in Hospitalized Patients [J] . Bin Wu, Jianghua Zhou, Wenxin Wang, 中国医学科学杂志（英文版） . 2021,第001期
2. Adverse associations of sedentary behavior with cancer incidence and all-cause mortality:A prospective cohort study [J] . Yuan Lin, Jie Cao, Chong Shen, 运动与健康科学（英文版） . 2021,第005期
3. Association of changes in waist circumference with cardiovascular disease and all-cause mortality among the elderly Chinese population:a retrospective cohort study [J] . Xue-Ning ZHANG, Hao ZHAO, Zhan SHI, 老年心脏病学杂志（英文版） . 2021,第003期
4. Independent and joint association of physical activity and sedentary behavior on all-cause mortality [J] . Wei Zhou, Wei Yan, Tao Wang, 中华医学杂志（英文版） . 2021,第023期
5. The association of grip strength with cardiovascular diseases and all-cause mortality in people with hypertension:Findings from the Prospective Urban Rural Epidemiology China Study [J] . Weida Liu, Salim Yusuf, Lisheng Liu, 运动与健康科学（英文版） . 2021,第006期
6. Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis [J] . Boregowda Umesha, Perisetti Abhilash, Nanjappa Arpitha, Frontiers in Medicine . 2020,第2期

机译：向护卫岛添加到护理标准降低严重Covid-19中的死亡率：系统审查和荟萃分析
7. Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis [J] . Umesha Boregowda, Abhilash Perisetti, Arpitha Nanjappa, Frontiers in Medicine . 2020,第a期

机译：向护卫岛添加到护理标准降低严重Covid-19中的死亡率：系统审查和荟萃分析
8. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients [J] . Klopfenstein T., Zayet S., Lohse A., Medecine et maladies infectieuses . 2020,第5期

机译：康斯康曼治疗减少了Covid-19患者的重症监护病房录取和/或死亡率
9. A National Study of the Mortality Effects of PM2.5 on All-Cause and Cause-Specific Mortality in the Contiguous U.S. [C] . Helen Tamura-Wicks, James Bennett, Matthew Bechle, Joint annual meeting of the International Society of Exposure Science and the International Society for Environmental Epidemiology . 2018

机译：一项全国性研究，研究了PM2.5对美国连续性全因和特定原因死亡率的死亡率影响。
10. A multi-state model to predict heart failure hospitalizations and all-cause mortality in outpatients with heart failure with reduced ejection fraction: Model derivation and internal validation. [D] . Upshaw, Jenica N. 2015

机译：预测射血分数降低的心力衰竭门诊患者的心力衰竭住院和全因死亡率的多状态模型：模型推导和内部验证。
11. Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis [O] . Umesha Boregowda, Abhilash Perisetti, Arpitha Nanjappa, 2020

机译：向护卫岛添加到护理标准降低严重Covid-19中的死亡率：系统审查和荟萃分析
12. >Association Analysis of Hyperlipidemia with the 28-Day All-Cause mortality of COVID-19 in Hospitalized Patients [O] . 2019

机译：高脂血症的关联分析与住院患者住院患者的28天全因死亡率
13. Morbidity and Mortality Weekly Report, Volume 49, Number RR-12, November 10,2000. Strategies for Reducing Exposure to Environmental Tobacco Smoke, Increasing Tobacco-Use Cessation, and Reducing Initiation in Communities and Health-Care Systems. A Report o [R] . 2000

机译：发病率和死亡率每周报告，第49卷，RR-12号，2000年11月10日。减少暴露于环境烟草烟雾，增加烟草使用戒烟和减少社区和卫生保健系统启动的战略。报告o

In COVID-19, tocilizumab reduces all-cause mortality at 28 d.

摘要

著录项

相似文献

相关主题

期刊订阅